Amphetamine Derivatives as Monoamine Oxidase Inhibitors [PDF]
Frontiers in Pharmacology, 2020 Amphetamine and its derivatives exhibit a wide range of pharmacological activities, including psychostimulant, hallucinogenic, entactogenic, anorectic, or antidepressant effects.
Miguel Reyes-Parada +3 more
doaj +3 more sources
Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders [PDF]
Molecules, 2019 Monoamine oxidase inhibitions are considered as important targets for the treatment of depression, anxiety, and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases.
Priyanka Dhiman +4 more
doaj +3 more sources
Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. [PDF]
Neural Regen Res, 2023 Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson’s disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also
Alborghetti M +5 more
europepmc +2 more sources
Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. [PDF]
Health Psychol Res, 2022 Monoamine oxidase inhibitors (MAOI) are a class of drugs that were originally developed for the treatment of depression but have since been expanded to be used in management of affective and neurological disorders, as well as stroke and aging-related ...
Edinoff AN +8 more
europepmc +2 more sources
Molecules, 2021 Despite not being utilized as considerably as other antidepressants in the therapy of depression, the monoamine oxidase inhibitors (MAOIs) proceed to hold a place in neurodegeneration and to have a somewhat broad spectrum in respect of the treatment of ...
Tapan Behl +9 more
doaj +2 more sources
Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action. [PDF]
Front Pharmacol, 2021 Chronic inflammatory diseases are debilitating, affect patients’ quality of life, and are a significant financial burden on health care. Inflammation is regulated by pro-inflammatory cytokines and chemokines that are expressed by immune and non-immune ...
Ostadkarampour M, Putnins EE.
europepmc +2 more sources
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. [PDF]
Curr Neuropharmacol, 2019 Three inhibitors of type-B monoamine oxidase (MAOB), selegiline, rasagiline, and safinamide, are used for the treatment of Parkinson’s disease (PD). All three drugs improve motor signs of PD, and are effective in reducing motor fluc-tuations in patients ...
Alborghetti M, Nicoletti F.
europepmc +2 more sources
Effects of Natural Monoamine Oxidase Inhibitors on Anxiety-Like Behavior in Zebrafish [PDF]
Frontiers in Pharmacology, 2021 Monoamine oxidases (MAO) are a valuable class of mitochondrial enzymes with a critical role in neuromodulation. In this study, we investigated the effect of natural MAO inhibitors on novel environment-induced anxiety by using the zebrafish novel tank ...
Oihane Jaka +8 more
doaj +2 more sources
Natural based piperine derivatives as potent monoamine oxidase inhibitors: an in silico ADMET analysis and molecular docking studies [PDF]
BMC Chemistry, 2020 Neurodegenerative disorders follow numerous pathological ways concerning overexpression of monoamine oxidase and formation of reactive oxygen species.
Priyanka Dhiman +2 more
doaj +2 more sources
Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors
Frontiers in Chemistry, 2018 Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine. Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression ...
Sanna Rauhamäki +20 more
doaj +2 more sources